SCHEMBL4520372

SCHEMBL4520372

Cn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(Cc3c(F)cc(F)cc3F)nc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.37
MAPK14 Q16539 3/20 0.35
BRD9 Q9H8M2 1/20 0.35
DRD1 P21728 2/20 0.35
DRD5 P21918 2/20 0.35
MAT2A P31153 1/20 0.35
ALDH1A2 O94788 1/20 0.35
ALDH1A3 P47895 1/20 0.35
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
XBP1 P17861 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
KCNN2 Q9H2S1 1/20 0.33
KCNN3 Q9UGI6 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HKDC1 Q2TB90 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4521285 0.93 SMN1; SMN2 (0.39) MAPK14MAT2AALDH1A2ALDH1A3LMNA
SCHEMBL4515658 0.91 MAPT (0.39) MAPK14DRD1DRD5ALDH1A2ALDH1A3
SCHEMBL4521219 0.91 MALT1 (0.35) MAPK14BRD9ALDH1A2ALDH1A3POLB
SCHEMBL4510075 0.90 GRM1 (0.37) MAPK14BRD9NPSR1POLBYTHDC1
SCHEMBL4523638 0.89 GSR (0.41) GSRMAPK14BRD9DRD1DRD5
SCHEMBL4513062 0.88 DRD1 (0.36) GSRMAPK14BRD9DRD1DRD5
SCHEMBL4524609 0.88 DRD1 (0.36) GSRMAPK14DRD1DRD5LMNA
SCHEMBL4521209 0.88 ALDH1A3 (0.39) GSRMAPK14DRD1DRD5MAT2A
SCHEMBL4514651 0.88 TP53 (0.37) MAPK14BRD9LMNAHTTNPSR1
SCHEMBL4530785 0.88 MAT2A (0.38) GSRBRD9MAT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 GSR 1941/4885MAPK14 3169/4885BRD9 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.